肺力咳胶囊联合沙美特罗氟替卡松治疗对慢性阻塞性肺疾病稳定期患者肺功能的影响观察  

Effect observation of Feilike capsule combined with salmeterol/fluticasoneon on pulmonary function in patients with stable chronic obstructive pulmonary disease

作　　者：栗广升 LI Guang-sheng(Taierzhuang District People's Hospital,Zaozhuang 277400,China)

机构地区：[1]山东省枣庄市台儿庄区人民医院,277400

出　　处：《中国实用医药》2024年第15期91-93,共3页China Practical Medicine

摘　　要：目的观察肺力咳胶囊联合沙美特罗氟替卡松治疗对慢性阻塞性肺疾病(COPD)稳定期患者肺功能的影响。方法64例慢性阻塞性肺疾病稳定期患者,随机分为观察组和对照组,每组32例。所有患者均给予氧疗、营养支持、心理干预、肺康复、止咳化痰等基础治疗,在此基础上对照组给予沙美特罗氟替卡松干粉吸入剂治疗,观察组在对照组的基础上予肺力咳胶囊治疗。比较两组患者治疗前后的第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、6 min步行试验(6MWT)、Borg评分以及药物治疗期间不良反应发生率。结果治疗后,两组患者FEV1、FEV1/FVC均有改善,且观察组FEV1(2.52±0.51)L、FEV1/FVC(76.62±4.20)%相比对照组的(2.07±0.20)L、(74.66±3.20)%改善更明显,差异具有统计学意义(P<0.05)。治疗后,观察组患者6MWT(350.18±9.34)m、Borg评分(2.62±0.80)分优于对照组的(215.35±8.46)m、(3.40±0.76)分,差异有统计学意义(P<0.05)。观察组发生声音嘶哑1例、关节痛1例,不良反应发生率为6.3%;对照组发生头痛3例,不良反应发生率为9.4%,两组不良反应发生率比较差异无统计学意义(P>0.05)。上述症状均未治疗,可自行消失。结论肺力咳胶囊联合沙美特罗氟替卡松治疗可明显改善慢性阻塞性肺疾病稳定期患者肺功能,使患者活动耐量增加,且药物联用不良反应少,从而改善了患者的生活质量。Objective To observe the effect of Feilike capsule combined with salmeterol/fluticasoneon on pulmonary function in patients with stable chronic obstructive pulmonary disease(COPD).Methods 64 patients with stable chronic obstructive pulmonary disease were randomly divided into an observer and a control group,with 32 cases in each group.All patients were given basic treatments such as oxygen therapy,nutritional support,psychological intervention,pulmonary rehabilitation,cough and sputum relief.On this basis,the control group was given,salmeterol fluticasone dry powder inhaler,and the observation group was given Feilike capsule on the basis of the control group.The forced expiratory volume in one second(FEV1),FEV1/forced vital capacity(FVC),6-min walking test(6MWT),Borg score and the incidence of adverse reactions during treatment were compared between the two groups.Results After treatment,FEV1 and FEV1/FVC improved in both groups compared to those before treatment;the observation group had FEV1 of(2.52±0.51)L and FEV1/FVC of(76.62±4.20)%,which were more obvious compared with(2.07±0.20)L and(74.66±3.20)%in the control group;the difference was statistically significant(P<0.05).After treatment,the observation group had 6MWT of(350.18±9.34)m and Borg score of(2.62±0.80)points,which were better than(215.35±8.46)m and(3.40±0.76)points in the control group and the difference was statistically significant(P<0.05).In the observation group,there was 1 case of hoarseness and 1 case of arthralgia,and the incidence of adverse reactions was 6.3%;in the control group,there were 3 cases of headache,and the incidence of adverse reactions was 9.4%.The difference between the two groups was not statistically significant(P>0.05).All of the above symptoms were untreated and could disappear on their own.Conclusion Feilike capsule combined with salmeterol/fluticasone can significantly improve the lung function of patients with stable chronic obstructive pulmonary disease,increase their activity tolerance,and reduce the adverse re

关 键 词：肺力咳胶囊 沙美特罗氟替卡松 慢性阻塞性肺疾病 稳定期 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]